PhaseRx (PZRX) Upgraded to Sell at ValuEngine

ValuEngine upgraded shares of PhaseRx (NASDAQ:PZRX) from a strong sell rating to a sell rating in a report published on Friday.

Separately, Laidlaw lowered shares of PhaseRx from a buy rating to a neutral rating in a report on Friday, October 13th.

Shares of PhaseRx (PZRX) opened at $0.28 on Friday. PhaseRx has a 1-year low of $0.22 and a 1-year high of $1.95. The company has a current ratio of 2.14, a quick ratio of 2.14 and a debt-to-equity ratio of -12.03.

PhaseRx (NASDAQ:PZRX) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.14.

An institutional investor recently raised its position in PhaseRx stock. Vanguard Group Inc. increased its position in shares of PhaseRx Inc (NASDAQ:PZRX) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,182 shares of the company’s stock after acquiring an additional 5,500 shares during the quarter. Vanguard Group Inc. owned 1.22% of PhaseRx worth $135,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “PhaseRx (PZRX) Upgraded to Sell at ValuEngine” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PhaseRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx and related companies with's FREE daily email newsletter.

Leave a Reply